Child Growth According to Maternal and Child HIV Status in Zimbabwe

Adetayo O. Omoni, Robert Ntozini, Ceri Evans, Andrew J. Prendergast, Lawrence H. Moulton, Parul S. Christian, Jean H. Humphrey

Research output: Research - peer-reviewArticle

Abstract

BACKGROUND:: Growth failure is common among HIV-infected infants, but there are limited data on the effects of HIV exposure or timing of HIV acquisition on growth. METHODS:: 14110 infants were enrolled in the ZVITAMBO trial in Zimbabwe before the availability of antiretroviral therapy (ART) or co-trimoxazole. Anthropometric measurements were taken from birth through 12-24 months of age. Growth outcomes were compared between 5 groups of children: HIV-infected in utero (IU), intrapartum (IP) or postnatally (PN); HIV-exposed uninfected (HEU); and HIV-unexposed. RESULTS:: Growth failure was common across all groups of children. Compared to HIV-unexposed children, IU, IP and PN-infected children had significantly lower length-for-age and weight-for-length Z-scores throughout the first two years of life. At 12 months, odds ratios for stunting were higher in IU infants (6.25, 95%CI 4.20, 9.31) and IP infants (4.76, 95%CI 3.58, 6.33) than PN infants (1.70, 95%CI 1.16, 2.47). Compared to HIV-unexposed infants, HEU infants at 12 months had odds ratios for stunting of 1.23 (95%CI 1.08, 1.39) and wasting of 1.56 (95%CI 1.22, 2.00). CONCLUSIONS:: HIV-infected infants had very high rates of growth failure during the first 2 years of life, particularly if infected in utero or intrapartum, highlighting the importance of early infant diagnosis and ART. HEU infants had poorer growth than HIV-unexposed infants in the first 12 months of life.

LanguageEnglish (US)
JournalPediatric Infectious Disease Journal
DOIs
StateAccepted/In press - Feb 13 2017

Fingerprint

Zimbabwe
Mothers
HIV
Growth
Growth Disorders
Odds Ratio
Therapeutics
Sulfamethoxazole Drug Combination Trimethoprim
Early Diagnosis
Parturition
Weights and Measures

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Child Growth According to Maternal and Child HIV Status in Zimbabwe. / Omoni, Adetayo O.; Ntozini, Robert; Evans, Ceri; Prendergast, Andrew J.; Moulton, Lawrence H.; Christian, Parul S.; Humphrey, Jean H.

In: Pediatric Infectious Disease Journal, 13.02.2017.

Research output: Research - peer-reviewArticle

@article{9dae0ebc88734ffaaf94801be7966ca0,
title = "Child Growth According to Maternal and Child HIV Status in Zimbabwe",
abstract = "BACKGROUND:: Growth failure is common among HIV-infected infants, but there are limited data on the effects of HIV exposure or timing of HIV acquisition on growth. METHODS:: 14110 infants were enrolled in the ZVITAMBO trial in Zimbabwe before the availability of antiretroviral therapy (ART) or co-trimoxazole. Anthropometric measurements were taken from birth through 12-24 months of age. Growth outcomes were compared between 5 groups of children: HIV-infected in utero (IU), intrapartum (IP) or postnatally (PN); HIV-exposed uninfected (HEU); and HIV-unexposed. RESULTS:: Growth failure was common across all groups of children. Compared to HIV-unexposed children, IU, IP and PN-infected children had significantly lower length-for-age and weight-for-length Z-scores throughout the first two years of life. At 12 months, odds ratios for stunting were higher in IU infants (6.25, 95%CI 4.20, 9.31) and IP infants (4.76, 95%CI 3.58, 6.33) than PN infants (1.70, 95%CI 1.16, 2.47). Compared to HIV-unexposed infants, HEU infants at 12 months had odds ratios for stunting of 1.23 (95%CI 1.08, 1.39) and wasting of 1.56 (95%CI 1.22, 2.00). CONCLUSIONS:: HIV-infected infants had very high rates of growth failure during the first 2 years of life, particularly if infected in utero or intrapartum, highlighting the importance of early infant diagnosis and ART. HEU infants had poorer growth than HIV-unexposed infants in the first 12 months of life.",
author = "Omoni, {Adetayo O.} and Robert Ntozini and Ceri Evans and Prendergast, {Andrew J.} and Moulton, {Lawrence H.} and Christian, {Parul S.} and Humphrey, {Jean H.}",
year = "2017",
month = "2",
doi = "10.1097/INF.0000000000001574",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Child Growth According to Maternal and Child HIV Status in Zimbabwe

AU - Omoni,Adetayo O.

AU - Ntozini,Robert

AU - Evans,Ceri

AU - Prendergast,Andrew J.

AU - Moulton,Lawrence H.

AU - Christian,Parul S.

AU - Humphrey,Jean H.

PY - 2017/2/13

Y1 - 2017/2/13

N2 - BACKGROUND:: Growth failure is common among HIV-infected infants, but there are limited data on the effects of HIV exposure or timing of HIV acquisition on growth. METHODS:: 14110 infants were enrolled in the ZVITAMBO trial in Zimbabwe before the availability of antiretroviral therapy (ART) or co-trimoxazole. Anthropometric measurements were taken from birth through 12-24 months of age. Growth outcomes were compared between 5 groups of children: HIV-infected in utero (IU), intrapartum (IP) or postnatally (PN); HIV-exposed uninfected (HEU); and HIV-unexposed. RESULTS:: Growth failure was common across all groups of children. Compared to HIV-unexposed children, IU, IP and PN-infected children had significantly lower length-for-age and weight-for-length Z-scores throughout the first two years of life. At 12 months, odds ratios for stunting were higher in IU infants (6.25, 95%CI 4.20, 9.31) and IP infants (4.76, 95%CI 3.58, 6.33) than PN infants (1.70, 95%CI 1.16, 2.47). Compared to HIV-unexposed infants, HEU infants at 12 months had odds ratios for stunting of 1.23 (95%CI 1.08, 1.39) and wasting of 1.56 (95%CI 1.22, 2.00). CONCLUSIONS:: HIV-infected infants had very high rates of growth failure during the first 2 years of life, particularly if infected in utero or intrapartum, highlighting the importance of early infant diagnosis and ART. HEU infants had poorer growth than HIV-unexposed infants in the first 12 months of life.

AB - BACKGROUND:: Growth failure is common among HIV-infected infants, but there are limited data on the effects of HIV exposure or timing of HIV acquisition on growth. METHODS:: 14110 infants were enrolled in the ZVITAMBO trial in Zimbabwe before the availability of antiretroviral therapy (ART) or co-trimoxazole. Anthropometric measurements were taken from birth through 12-24 months of age. Growth outcomes were compared between 5 groups of children: HIV-infected in utero (IU), intrapartum (IP) or postnatally (PN); HIV-exposed uninfected (HEU); and HIV-unexposed. RESULTS:: Growth failure was common across all groups of children. Compared to HIV-unexposed children, IU, IP and PN-infected children had significantly lower length-for-age and weight-for-length Z-scores throughout the first two years of life. At 12 months, odds ratios for stunting were higher in IU infants (6.25, 95%CI 4.20, 9.31) and IP infants (4.76, 95%CI 3.58, 6.33) than PN infants (1.70, 95%CI 1.16, 2.47). Compared to HIV-unexposed infants, HEU infants at 12 months had odds ratios for stunting of 1.23 (95%CI 1.08, 1.39) and wasting of 1.56 (95%CI 1.22, 2.00). CONCLUSIONS:: HIV-infected infants had very high rates of growth failure during the first 2 years of life, particularly if infected in utero or intrapartum, highlighting the importance of early infant diagnosis and ART. HEU infants had poorer growth than HIV-unexposed infants in the first 12 months of life.

UR - http://www.scopus.com/inward/record.url?scp=85012935034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012935034&partnerID=8YFLogxK

U2 - 10.1097/INF.0000000000001574

DO - 10.1097/INF.0000000000001574

M3 - Article

JO - Pediatric Infectious Disease Journal

T2 - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

ER -